Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

BTK inhibition potentiates anti-PD-L1 treatment in murine melanoma: potential role for MDSC modulation in immunotherapy

Cancer Immunology Immunotherapy(2023)10.1007/s00262-023-03497-1Source: DataRank Database

BTK inhibition potentiates anti-PD-L1 treatment in murine melanoma: potential role for MDSC modulation in immunotherapy is a research paper published in Cancer Immunology Immunotherapy (2023). On theSindex it has a DataRank of 0. It has been cited 15 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access15 citations

Download PDF

Cite:

Linked data & code

nct

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (9 grants)Impact (FWCI 1.45)OA: greenTopics (52)IDs (PubMed, PMC, OpenAlex)Annotations (1)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (20)

Colin D. Angell ORCID,Himanshu Savardekar ORCID,Debasish Sundi ORCID,David Abood,Brooke Benner ORCID

Live enrichment

PubMed:37528320 PMC:PMC10592087 OpenAlex:https://openalex.org/W4385477422

National Institutes of Health

Grant: T32AI 106704-01A1

National Institutes of Health

Grant: 1T32 GM139784-01A1

American Urological Association Foundation

Grant: Urology Care Foundation Research Scholars Award

National Cancer Institute

Grant: UM1CA186712

NIGMS NIH HHS

Grant: T32 GM139784

NIAID NIH HHS

Grant: T32 AI106704

National Institutes of Health

Grant: 5T32GM139784-03

Medical Scientist Training Program - The Ohio State University

National Institutes of Health

Grant: 5T32AI106704-09

Advanced Research Training in Immunology for Surgery Trainees (ARTIST)

National Institutes of Health

Grant: 1UM1CA186712-01

Experimental Therapeutics of Anti-Cancer Agents with Phase I Emphasis

FWCI

1.45

Citation Percentile

0.8%

Citation Trend

2024

2025

2026

greenLicense: Springer Nature TDM

repositoryhttps://pmc.ncbi.nlm.nih.gov/articles/PMC10592087/pdf/262_2023_Article_3497.pdf

publisherhttps://link.springer.com/content/pdf/10.1007/s00262-023-03497-1.pdf

publisherhttps://link.springer.com/article/10.1007/s00262-023-03497-1/fulltext.html

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/10592087

Fields of Study

Immune cells in cancerCancer Immunotherapy and BiomarkersImmune Cell Function and Interaction03 medical and health sciences0302 clinical medicineHumansMiceAnimalsAgammaglobulinaemia Tyrosine KinaseProtein-Tyrosine KinasesMyeloid-Derived Suppressor CellsB7-H1 AntigenImmunotherapyAntineoplastic AgentsMelanoma

MeSH Terms

Myeloid-Derived Suppressor CellsAgammaglobulinaemia Tyrosine KinaseAnimalsAntineoplastic AgentsHumansImmunotherapyMelanomaProtein-Tyrosine KinasesMiceB7-H1 Antigen

Keywords

Bruton's tyrosine kinaseIbrutinibCancer researchPharmacologyTyrosine kinaseImmune systemMelanomaCancer immunotherapyImmunotherapyChemistryMedicineImmunologySignal transductionLeukemiaChronic lymphocytic leukemiaBiochemistryMdscBtkImmune Checkpoint BlockadeMiceMyeloid-Derived Suppressor CellsAgammaglobulinaemia Tyrosine KinaseHumansAnimalsAntineoplastic AgentsProtein-Tyrosine KinasesB7-H1 Antigen

Sustainable Development Goals

SDG 0: Good health and well-being